Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q2 EPS of $1.08, $0.06 better than the analyst estimate of $1.02.

Financial Guidance

Cash position. As of June 30, 2026, Rocket had cash, cash equivalents and investments of $283.7 million. Based on its current operating plan, Rocket expects its cash, cash equivalents and investments as of June 30, 2026, to fund operations into the second quarter of 2028.

For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.